Kodiak Sciences (KOD) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic progress and pipeline overview

• Three lead assets—KSI-101, tarcocimab, and KSI-501—are in late-stage development, targeting major retinal indications with strong scientific validation and commercial potential.

• Advancing three Phase 3 retina programs with topline data readouts expected in 2026–2027, targeting wet AMD, diabetic retinopathy, retinal vein occlusion, and MESI.

• Additional pipeline assets include next-generation bispecifics (KSI-102, KSI-103), RNAi programs, and preclinical assets for inflammation, glaucoma, and geographic atrophy.

• Proprietary bioconjugate/ABC® platform enables modular drug development across diverse APIs, supporting long-term value creation and tailored release for ophthalmic and systemic indications.

• Commercial manufacturing infrastructure is established and validated, supporting large-scale launches and rapid product launches upon approval.

Clinical development and data highlights

• KSI-101 Phase I 24-week data to be presented in February; Phase III PEAK top-line data expected Q4 this year, PINNACLE in Q2 2027.

• Tarcocimab GLOW2 top-line data expected this quarter; DAYBREAK (wet AMD) readout in Q3, with BLA filing planned for mid-2026.

• KSI-501 DAYBREAK data also expected in Q3, with potential for BLA in 2027.

• Tarcocimab demonstrated 6-month durability in 75% of RVO patients and superior efficacy in diabetic retinopathy with only two doses per year.

• KSI-101 Phase 1b APEX study showed >10 letter vision gains by week 4 and ≥90% fluid resolution at higher doses.

Market opportunity and competitive landscape

• Retinal vascular diseases represent a $15 billion market, with significant unmet needs for therapies offering both high immediacy and durability.

• Over 150,000 initial MESI patients in the US, with KSI-101 targeting this greenfield market and showing strong early data.

• Current biologics lack combined high immediacy and durability; new therapies aim to fill this gap and outperform current standards.

• Real-world data show most patients on existing therapies do not achieve label-promised durability, highlighting unmet needs.

• Physician feedback indicates strong interest in new therapies that avoid steroid-related complications.